Thyroid Cancer

Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.

Latest Discoveries

FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Thyroid Cancer
Published
August 13, 2026

In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…

Primary source cited

Last reviewed

Major Advances

FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Thyroid Cancer
Published
August 13, 2026

In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…

Primary source cited

Last reviewed

FDA Approvals

Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.

FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer

Regulatory status: FDA ApprovedEvidence stage: Later-Stage Human
Cancer type
Thyroid Cancer
Population
Patients aged 2 to 20 with locally advanced or metastatic RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, enrolled in the primary efficacy population of the international, single-arm, multicohort, phase 1/2 LIBRETTO-121 trial.
View approval details
Last reviewed
2026-08-13

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Pediatric patients aged 2 and older with RET-altered metastatic thyroid cancer, or other RET-altered solid tumors that are advanced or metastatic and require systemic therapy, that have progressed on or are intolerant to prior therapy, or for whom there is no satisfactory alternative treatment.
Biomarker requirement
RET gene alteration (fusion or mutation)
Decision date
2024-05-29
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Applies to the exact indication stated.

Refine your search

Related resources

Trusted resources: official cancer information

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.